Ergoteles’s Collegium Pharmaceutical COLL Stock Holding History

Ergoteles’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-11,711	Closed	-$219K	–	1280
2021 Q4	$219K	Buy	+11,711	New	+$228K	0.01%	980

Other funds holding COLL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ergoteles's COLL Position: Q1 2022 in Review

Ergoteles sold out of Collegium Pharmaceutical (COLL) in Q1 2022, closing a stake of 11,711 shares — an estimated $219K sold.

Ergoteles first reported a position in COLL in Q4 2021 and held it in 1 quarter. The position peaked at $219K in Q4 2021. 172 funds tracked by Wall St. Rank hold COLL as of Q1 2022.

Ergoteles reported no remaining Collegium Pharmaceutical position as of Q1 2022 after selling out during the quarter.
Ergoteles sold 11,711 Collegium Pharmaceutical shares in Q1 2022, an estimated $219K.
Ergoteles first reported a position in Collegium Pharmaceutical in Q4 2021 and held it in 1 quarter.
Ergoteles's Collegium Pharmaceutical position peaked at $219K in Q4 2021.
172 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2022.

Based on Ergoteles's 13F filing for Q1 2022, filed 13 May 2022.